RBC Capital lowered the firm’s price target on Alnylam (ALNY) to $465 from $500 but keeps an Outperform rating on the shares after meeting with its management team following its FY26 net product revenue outlook. On Amvuttra, the company clarified that the soft November was driven by a few one-offs and highlighted a “very impressive December”, the analyst tells investors in a research note. On 2026, Alnylam announced a splashy guide, primarily driven by TTR – transthyretin amyloidosis, the firm added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target lowered to $376 from $479 at Wells Fargo
- Top 3 Trending Stocks, According to Analysts – 1/15/2026
- Alnylam: Near-Term Amvuttra Shortfall Outweighed by Robust TTR Growth Outlook and Strengthened Long-Term Leadership Position
- Alnylam Pharmaceuticals: Strong Long-Term Growth Strategy But Balanced Risk/Reward Supports Hold Rating
- Alnylam 2026 guidance reflects continued momentum, says H.C. Wainwright